We are a not for profit organisation with the mission to put new and improved medicines into the hands of people who need them most.


The Rotavirus Vaccine Program at the Murdoch Children’s Research Institute has published results from their study evaluating the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB) in preventing rotavirus gastroenteritis. Amanda Handley, Director at Medicines Development, has been providing project management services on this program since January 2013. Congratulations to all the program team […]

Read more

Medicines Development for Global Health is delighted to announce the publication of the moxidectin Phase III study in the Lancet. The paper’s authors, coordinated by the previous Sponsor of moxidectin, the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, concluded that “Moxidectin would therefore be expected to reduce parasite transmission between treatment […]

Read more

Medicines Development for Global Health is pleased to announce the submission of a New Drug Application for moxidectin as an oral treatment for river blindness to the US Food and Drug Administration (FDA). The FDA have also confirmed that moxidectin has qualified for priority review. Please see attached press release for further details. The FDA […]

Read more

Who We Are

We are an independent not-for-profit global health company dedicated to the development of affordable medicines and vaccines.

Medicines Development Limited (Medicines Development for Global Health) was founded in 2005 by Mark Sullivan. Our principals have in excess of 60 years combined drug development experience. As a not-for-profit, Medicines Development for Global Health uses all funds in excess of running costs for the development of medicines and vaccines that may have limited commercial opportunity, but which address important unmet medical needs.

Medicines Development for Global Health applies pharmaceutical industry development approaches in the global health setting.

Why We Do What We Do

There is a need for innovative solutions for development and delivery of medicines and vaccines for diseases that predominate in low and middle income countries. Opportunities identified regionally (for both candidate products and diseases unique to the region) are our focus.

We are driven by giving back.

How We Work

Our skill is in applying industry-proven methodologies and standard operating procedures to undertake all stages of regulatory-compliant drug and vaccine development.  We concentrate on providing project leadership, clinical research management and project management, sourcing the balance of the project team skills from expert service providers, no matter where they are located, to match the project.

We believe in a differentiated pricing model so that funds from commercial sales can be used to make medications accessible to those most in need. This model allows us to deliver on our social goals while also ensuring financial return for our funders.

Our development programs

Moxidectin Program

Onchocerciasis (river blindness) is a parasitic disease caused by the worm Onchocerca volvulus that is transmitted from person to person through the bite of black flies. The flies live and breed near fast flowing rivers and streams. Adult worms live in nodules under the skin for up to 15 years and continuously produce millions of microscopic larvae called microfilariae that infest the skin and eyes. Symptoms of the disease result from these larvae and cause impaired vision and blindness, severe itching, dermatitis, depigmentation and thinning of the skin, and swollen lymph glands.  In addition people suffer low self-esteem, experience social isolation, and worry that they will never marry. Poverty and famine are also increased as people move away from crop producing fertile river areas to less fertile areas to avoid the fly’s habitat and thereby risk of contracting the disease.

While considerable progress has been made in the treatment of river blindness, the disease has not been eradicated and still causes serious morbidity and mortality in sub-Saharan Africa. Moxidectin is an important potential new therapeutic option for river blindness and other neglected diseases affecting over 2 billion people. It has an excellent safety profile in preclinical and clinical settings, broad anti-helminth and ectoparasite activity.

From the late 1990s, the WHO-based Special Programme for Research and Training in Tropical Diseases (WHO/TDR) has worked extensively with industry, patient and community groups to evaluate the use of moxidectin for the treatment of onchocerciasis.  The final stages of human studies in river blindness have now been completed and moxidectin has been shown to be well tolerated and effective against the disease.

Our initial focus is the registration of moxidectin for the treatment of river blindness.  This process is being funded via a $US 10 million investment by the Global Health Investment Fund I, LLC (GHIF) which will be used to support the manufacture and testing of moxidectin, the performance of  further clinical studies as required and the compilation of the regulatory dossier as part of the New Drug Application. Upon successful registration of moxidectin, we have committed to deliver moxidectin for onchocerciasis treatment  on a  cost recovery basis  and, with GHIF, to continue to research other potential human uses of moxidectin.

Medicines Development for Global Health
Christopher Egerton-Warburton, Fund Manager at the Global Health Investment Fund and Mark Sullivan, CEO of Medicines Development, sign the $10 million funding arrangement.
Global Health Programs

Very few interventions can be as impactful as a medicine to treat or prevent a disease.

Medicine Development for Global Health

Medicines Development for Global Health has significant expertise in the execution of global health medicine and vaccine development.  The diagram above which summarises some of the programs we have undertaken, and include both Medicines Development for Global Health proprietary programs and those where Medicines Development for Global Health works in collaboration.  Medicines Development is Australia’s leading provider of  clinical and development management services to the biopharmaceutical industry.  We provide clinical research design and execution as a virtual member of the company’s team rather than an arms length, outsourced activity.  We coordinate the preparation of development plans focused on regulatory and commercial outcomes and develop logical budgets, then help to execute against those plans.

Consulting Services

What we do for biotechnology companies

Medicines Development is Australia’s leading provider of development management to the biopharmaceutical industry. We offer to biotechnology companies a fee for service program to assist with their development program by providing the ‘in house’ pivotal coordination role on a project by project basis to bring disparate elements toward regulatory compliant clinical development. We coordinate the preparation of development plans focused on regulatory and commercial outcomes and develop logical budgets, then execute against those plans.

Corporate highlights

Medicines Development has led and project managed the development of 14 pre-clinical and clinical candidates, and contributed to the development of many more. For more information on our commercial service provision, please email us.

Our Team


David Cooper – Board Member

David Cooper BSc (Med) MBBS (Syd), MD, DSc (UNSW), FRACP, FRCPA, FRCP, FAA (19 April 1949 – 18 March 2018) was Scientia Professor and Director of the Kirby Institute. David Was a founding Board member, a Member of the company and friend who will be greatly missed. Vale David Cooper.

Lorna Meldrum – Board Member, Chair of the Board

Lorna has enjoyed a successful 25-year career in the pharmaceutical industry, encompassing clinical research, business development, marketing and sales, all across a wide variety of therapeutic areas, including Respiratory, CNS, Cardiopulmonary, Metabolic, Psychiatry, Neurology, HIV and Vaccines. She has worked in the US, Europe and Asia Pacific. She immigrated to Australia in 2002 and worked for GSK Australia as the Commercial Vice President for five years. In 2009, she established Ikaria Australia Ltd Pty., a biotherapeutics company that commercialises drugs and devices for intensive care medicine. Lorna is currently Vice President, Commercial Operations of bioCSL Ltd Lorna graduated with a PhD in Neurobiology (University College London); BSc in Pharmacology (University of Glasgow) and went on to hold academic positions at the Cardiothoracic Institute at the Royal Brompton Hospital (London) and at the Royal Post Graduate Medical School (London).

Mark Sullivan – Founder, Managing Director and Board Member

Founder and Managing Director of Medicines Development Limited, a biopharmaceutical company focussing on developing and delivering medicines for diseases of low and middle income countries. Key career highlights include 11 years executive management, Advisory Board and Board of Directors experience in biotechnology and 28 years experience in clinical development within biotechnology, large pharmaceutical, contract services and academic sectors. Drug development experience encompasses project leadership of 5 products, including moxidectin for the treatment of onchocerciasis, and extensive practical experience of implementation of clinical first exposure, proof of concept, phase 2, global phase 3, phase 3b design and implementation, and phase 4 clinical studies. Significant contributor to three successful global registrational programs. Chief Operating Officer of Australia’s HIV vaccine design and development consortium responsible for designing, constructing, manufacturing and clinically evaluating a novel HIV vaccine. Extensive international experience having worked in operating company (UK 4 years), international head office (UK 6 years, US 2 years), contract research (Australia 1 year), and academic settings (Australia 3 years) with direct experience of drug development in 24 countries.

Andrew Wilks – Board Member

Andrew Wilks BSc PhD was most recently Chief Scientific Officer and founder of Cytopia. Prior to starting Cytopia, Andrew was at the Ludwig institute for Cancer Research in Melbourne where he discovered the JAK kinases. He holds an Honorary Professorship at Monash University (Melbourne), and was the inaugural winner of the Australian Biobusiness Award in 2007. Based in Melbourne Australia, Andrew co-founded SYN|thesis in 2007 and now oversees global operations.

Executive Team

Amanda Handley – Senior Director

In 2005 Amanda joined Medicines Development where she led the development of a therapeutic vaccine for HIV and is currently working on a low cost birth-dose oral rotavirus vaccine. Amanda has 15 years local and international experience in HIV immunology and new product research and development. Amanda completed a Masters in Public Health before joining Bavarian Nordic GmbH in Denmark and Germany with experience gained in pre-clinical, Phase I and II smallpox and viral vector vaccine development. Her responsibilities included managing the clinical analysis group and participation in product development teams.

Patty Holmes Fegan – Director

Patty joined Medicines Development in 2010 to add her commercial talents to the team. At MDL Patty is responsible for the overall business management of the company including legal, financial, HR and statutory reporting aspects. Patty’s business background includes working in the toy and fashion industries in NYC as variously Director of International Sales, Sales Manager, Sales Representative and fit model for a large multinational firms where she was able to combine her ability to speak six languages with her astute business knowledge.

Sally Kinrade – Vice President

Sally joined MDL in 2013 with twelve years clinical pharmacy and more than 20 years industry and management experience including 11 years in clinical research and operations, 2 years in commercial and 6 years in medical affairs at GlaxoSmithKline Australia. Three years as an independent industry consultant focused on clinical operations and scientific writing for industry, research and government clients. Prior to joining Medicines Development, Chief Operating Officer at Phosphagenics Limited, a publicly listed Australian biotechnology company with development projects in Phases I and II.

John Lambert – Senior Director

John joined MDL in 2016 to add his commercial experience as well as his vast experience working over the entire spectrum of drug discovery and development.  John’s former positions include COO at PolyActiva, Vice President Drug Development and Director, Drug Discovery at Biota Pharmaceuticals.  Prior to moving to industry in 2002, John was a Senior Lecturer at the University of Melbourne, an ARC QEII Fellow at the Australian National University and a post-doctoral fellow at Harvard University. John holds a first-class Honours degree in Science, a PhD. in organic chemistry from the University of Melbourne and is a Graduate of the Australian Institute of Company Directors.

Larry Ward – Vice President

Larry joined MDL in 2012 as a highly experienced biotechnology executive with broad R&D, product development, operational and general management experience, including manufacturing, pre-clinical and clinical development and regulatory affairs. He has direct experience in the development of therapeutic vaccines for HIV, HBV and cancer targets. He has more than 14 years’ experience in the biotechnology industry at companies including AMRAD and Virax in positions spanning from Laboratory Director through to CEO. Larry’s medical research experience is drawn from in excess of ten years’ as a senior medical researcher in leading Australian and international institutes.